DeutschNewstral
Article
Haaretz on 2018-10-18 04:30
Business in Brief: Teva Faces U.S. Setback on Migraine Drug
Related news
- HTeva Gets OK on Migraine Drug, Share Price Surgeshamodia.com
- Teva Loses Negotiations Over New Migraine Drug, Stock Falls 5 PercentHaaretz
Drug Maker Teva Faces a Crisis in IsraelThe New York Times
FDA approves Teva migraine drugbizjournals.com- Business in Brief: Teva Shares Drop After Rival Reports Progress on Alternative Multiple Sclerosis DrugHaaretz
- Business in Brief: Teva Threatened With Strike at Main Plant for Making Top-selling Copaxone DrugHaaretz
- Business in Brief: Teva Reaches $135m Settlement With Illinois Over Wholesale Drug PricesHaaretz
Teva shares rally as FDA approves troubled drugmaker’s migraine treatmenttimesofisrael.com- HExpress Scripts Covers Amgen, Lilly Migraine Drugs, Excludes Tevahamodia.com
- FRegeneron, Teva in retreat after drug setbackft.com
- Israel's Teva Halts Testing Alternative Use for Migraine DrugHaaretz
- Lilly Defeats Teva Patent Lawsuits Over Migraine DrugHaaretz
- The Ticker: After Delays, Teva to Launch Key Migraine Treatment in mid-SeptemberHaaretz
- Teva shares rise in Tel Aviv as migraine results buoy investorstimesofisrael.com
- Teva Shares Fall Amid Investor Worries FDA May Delay Launch of Migraine TreatmentHaaretz
- Business in Brief / Teva secures $33.75b loan for Allergan dealHaaretz
- Israel's Teva Sees Sharp Rise in Revenue Next Year Boosted by New Migraine DrugHaaretz
- Big setback for Teva after key Mylan shareholder backs Perrigo bidHaaretz
Eli Lilly ordered to pay $176.5 mln to Teva in US migraine drug patent trialThe Jerusalem Post (JPost.com)- U.S. Justice Department Sues Teva Over Alleged Drug KickbacksHaaretz